Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7868
Reference
Drug alert 23/2023
Name
Drug alert class 1 - 23 2023 – Class 1 medicines recall – action now including out of hours – NatPSA 2023/004/MHRA – Pharmaswiss Ceska republika s.r.o and distributor Bausch & Lomb UK LTD – Emerade 500 & 300 MCG solution for injection in pre-filled syringe
Categories
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
MEDICINES RECALL
Description
Pharmaswiss Česka republika s.r.o. and distributor Bausch & Lomb UK Limited is recalling all unexpired batches of Emerade 500 micrograms and Emerade 300 micrograms adrenaline auto-injectors (also referred to as pens) from patients. This is due to an issue identified during an ISO 11608 Design Assessment study where some auto-injectors failed to deliver the product or activated prematurely. The MHRA, in conjunction with the Department of Health & Social Care (DHSC) has established that there are sufficient supplies of alternative auto-injectors to allow for a recall at patient level.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2023-05-09 00:00:00
Click to go back to homepage